SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX
Clinical trials for SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX explained in plain language.
Never miss a new study
Get alerted when new SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX trials appear
Sign up with your email to follow new studies for SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Blood test guides gentler radiation for throat cancer
Disease control Recruiting nowThis study is testing whether a lower dose of radiation to the neck can be as effective as standard treatment for HPV-positive throat cancer, but with fewer side effects. About 90 adults with this type of cancer will receive the lower-dose radiation, and their response will be mo…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX
Phase: PHASE2 • Sponsor: University of Virginia • Aim: Disease control
Last updated Apr 01, 2026 21:48 UTC
-
Doctors test gentler, tailored treatments for common throat cancer
Disease control Recruiting nowThis study is testing two personalized approaches to treat early-stage throat cancer caused by HPV. The goal is to control the cancer effectively while using less intense treatments to reduce side effects. One approach starts with surgery, and the other uses tailored radiation an…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC
-
Doctors test cutting radiation to spare patients from harsh side effects
Disease control Recruiting nowThis study is testing whether doctors can safely reduce the amount of radiation given to head and neck cancer patients after surgery. The goal is to lower long-term side effects, like difficulty swallowing, without increasing the risk of the cancer coming back. About 500 patients…
Matched conditions: SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX
Phase: PHASE2, PHASE3 • Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC